Literature DB >> 11888088

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.

Neal S Goldstein1.   

Abstract

This study provides detailed staining results for 225 prostate adenocarcinomas, including 150 Gleason score 8, 9, and 10 adenocarcinomas with cytokeratins (CKs) 7, 20, 5/6, and 17, prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), carcinoembryonic antigen (CEA), WT1, thyroid transcription factor-1 (TTF-1), and villin. CK7 was reactive in 112 adenocarcinomas (49.8%). The percentage of CK7-reactive adenocarcinomas and the percentage of CK7-stained cells increased in higher Gleason score adenocarcinomas; most reactive neoplasms had CK7 staining of fewer than 25% of cells. CK20 had similar results. The percentage of PSA- and PAP-reactive adenocarcinomas and the percentage of stained cells in reactive neoplasms decreased in higher Gleason score adenocarcinomas. CK5/6 and CK17, WT1, CA-125, TTF-1, and villin were nonreactive. The prostate can be the primary site of metastatic adenocarcinoma that is nonreactive for PAP and PSA and has CK7 or CK20 reactivity in fewer than 50% of the cells. The likelihood that a metastatic adenocarcinoma is from the prostate is low if reactivity with any of the cytokeratin antibodies, CEA, TTF-1, CA-125, WT1, or villin is extensive.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888088     DOI: 10.1309/G6PR-Y774-X738-FG2K

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  30 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

Review 2.  Vaccine prevention of cancer: can endogenous antigens be targeted?

Authors:  Louis M Weiner; Rishi Surana; Joseph Murray
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

3.  Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.

Authors:  Jorge A Garcia
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

Review 4.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 5.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

6.  Prostatic acid phosphatase expression in human tissues.

Authors:  Thomas J Graddis; Catherine J McMahan; Jennifer Tamman; Keith J Page; James B Trager
Journal:  Int J Clin Exp Pathol       Date:  2011-03-22

Review 7.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

Review 8.  Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?

Authors:  Andrew L Laccetti; Sumit K Subudhi
Journal:  Curr Opin Urol       Date:  2017-11       Impact factor: 2.309

9.  Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death.

Authors:  M Tarján
Journal:  Indian J Urol       Date:  2010 Jan-Mar

10.  Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Authors:  Amanda H Seipel; Hemamali Samaratunga; Brett Delahunt; Fredrik Wiklund; Peter Wiklund; Johan Lindberg; Henrik Grönberg; Lars Egevad
Journal:  Virchows Arch       Date:  2014-07-25       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.